Nycomed pays $70 million for Acusphere contrast agent
This article was originally published in Clinica
Executive Summary
Acusphere is to receive up to $70m from Nycomed after it agreed to give the Danish company European development and marketing rights to its AI-700 ultrasound contrast agent, currently in phase III clinical trials for assessing myocardial perfusion in the diagnosis of coronary heart disease.